ReviewInternational journal of molecular sciences2022
The Interplay between Gut Microbiota and Parkinson's Disease: Implications on Diagnosis and Treatment.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Dissecting the causal links between gut microbiome, immune traits and polyp using genetic evidence.Frontiers in immunology · 2024Pooled it
- Developing a translational research framework for MDD: combining biomolecular mechanisms with a spiraling risk factor model.Frontiers in psychiatry · 2024Pooled it
- A qPCR-based approach targeting the microbial gene markerJournal of Parkinson's disease · 2026Article
- Oral Sodium Hyaluronate Reshapes Gut Microbiota Composition and Suppresses the LPS-TLR4/NF-κB Pathway to Exert Neuroprotection in MPTP-Induced Parkinson's Disease.International journal of molecular sciences · 2026Article
- Oral natural extracellular vesicles for biomedical applications: Advances and clinical perspectives.Journal of advanced research · 2026Review
- Gut-Brain Signaling in Parkinson's Disease: A Narrative Review.International journal of molecular sciences · 2026Review
- Age-driven dysbiosis: gut microbiota in the pathogenesis and treatment of aging disorders.Biogerontology · 2026Review
- Antioxidant and Anti-Inflammatory Activities of Probiotic Strains.International journal of molecular sciences · 2026Review
- Gut microbiota and brain aging: a comparative review of African and western populations.Frontiers in aging neuroscience · 2026Review
- Specific gut microbiota alterations and metabolic deficits in Parkinson's disease: a controlled comparison with functional constipation.Frontiers in cellular and infection microbiology · 2026Article
- Micro/Nanoparticles in the Nose-Brain Axis: Implications for Pathogenesis and Therapeutic Interventions.International journal of nanomedicine · 2026Review
- Navigating the duality of Akkermansia muciniphila.Nature microbiology · 2026Review
- Gut Microbiota and Dopamine: Producers, Consumers, Enzymatic Mechanisms, and In Vivo Insights.Bioengineering (Basel, Switzerland) · 2025Review
- Dopamine and the Gut Microbiota: Interactions Within the Microbiota-Gut-Brain Axis and Therapeutic Perspectives.International journal of molecular sciences · 2025Review
- Parkinson's Disease: The Epidemiology, Risk Factors, Molecular Pathogenesis, Prevention, and Therapy.MedComm · 2025Review
- The ketogenic diet in Parkinson's disease: a potential therapeutic strategy.Pharmacological reports : PR · 2025Review
- Metabolic modeling links gut microbiota to metabolic markers of Parkinson's disease.Gut microbes · 2025Article
- Review
- Neuroprotective Attributes of Gut-derived Urolithins in Parkinson's Disease.Molecular neurobiology · 2025Review
- Gut bacteria-derived metabolites and their implications in mental health and neurological diseases.World journal of microbiology & biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The bidirectional interaction between the gut microbiota (GM) and the Central Nervous System, the so-called gut microbiota brain axis (GMBA), deeply affects brain function and has an important impact on the development of neurodegenerative diseases. In Parkinson's disease (PD), gastrointestinal symptoms often precede the onset of motor and non-motor manifestations, and alterations in the GM composition accompany disease pathogenesis. Several studies have been conducted to unravel the role of dysbiosis and intestinal permeability in PD onset and progression, but the therapeutic and diagnostic applications of GM modifying approaches remain to be fully elucidated. After a brief introduction on the involvement of GMBA in the disease, we present evidence for GM alterations and leaky gut in PD patients. According to these data, we then review the potential of GM-based signatures to serve as disease biomarkers and we highlight the emerging role of probiotics, prebiotics, antibiotics, dietary interventions, and fecal microbiota transplantation as supportive therapeutic approaches in PD. Finally, we analyze the mutual influence between commonly prescribed PD medications and gut-microbiota, and we offer insights on the involvement also of nasal and oral microbiota in PD pathology, thus providing a comprehensive and up-to-date overview on the role of microbial features in disease diagnosis and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.